The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
We investigated the in vivo function of the B7 family member B7-H3 (also known as B7RP-2) by gene targeting. B7-H3 inhibited T cell proliferation mediated by antibody to T cell receptor or allogeneic antigen-presenting cells. B7-H3-deficient mice developed more severe airway inflammation than did wild-type mice in conditions in which T helper cells differentiated toward type 1 (T(H)1) rather than type 2 (T(H)2). B7-H3 expression was consistently enhanced by interferon-gamma but suppressed by interleukin 4 in dendritic cells. B7-H3-deficient mice developed experimental autoimmune encephalomyelitis several days earlier than their wild-type littermates, and accumulated higher concentrations of autoantibodies to DNA. Thus, B7-H3 is a negative regulator that preferentially affects T(H)1 responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, CD276 (B7-H3), known to augment Tregs and inhibit T cell responses (Costa et al., 2018, Prasad et al., 2004, Suh et al., 2003), was expressed most prominently on CAFs and TSKs.”
From Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma (2020) · cites this paper as Suh et al., 2003
In the citing paper
“B7H3 has been shown to promote tumor metastasis and invasion via suppression of both CD8+ and CD4 + T cell proliferation and activity86,87.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [87]
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“The idea that PD-1 has an immune inhibitory function is supported by the phenotype of PD-1-deficient mice, which develop lupus-like diseases or autoimmune dilated cardiomyopath”
BackgroundCD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717 · cited 1×
“gif" NDATA ITEM> ]> An optimal T cell response is achieved by a combination of signals delivered through the antigen-specific T cell receptor (TCR) and accessory signals that are either stimulatory or inhibitor”
BackgroundDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Cited by
Items 401–500 of 573
Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections
Zhou, D., & Ertl, H. C. J. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.1.63 · Cited by 12
“Functional studies support both stimulatory [53] and inhibitory [54] roles for B7-H3, whereas B7-H4 has negative regulatory functions [55-57] (Figure 2).”
BackgroundOmori, S., Muramatsu, K., Kawata, T., Miyawaki, E., Miyawaki, T., Mamesaya, N., Kawamura, T., Kobayashi, H., Nakashima, K., Wakuda, K., et al. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01353-8 · Cited by 13
Luan, S. (2025) · American Journal of Translational Research · doi:10.62347/iltr3848 · Cited by 15
Emerging Immunotherapy Targets in Early Drug Development
Araujo, D. M., Catani, G., Mirallas, O., Pretelli, G., Sánchez-Pérez, V., Vieito, M., Braña, I., Pujol‐Borrell, R., Garralda, E., & Hernando‐Calvo, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115394 · Cited by 15
“Both are primarily recognized for their immune-inhibitory functions, contributing to an immunosuppressive TME [62–64].”
Shen, Y., Fang, H., Xie, H., Zhu, S., Wang, X., Liu, S., Sui, J., Xu, Y. J., Bo, Y., Zhao, J., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02458-8 · Cited by 16
“As we all know that CD276 (B7-H3), a pivotal immune check-point, mediates multifaceted tumor immune evasion mechanisms, including reduced CD8 ་ T cells and natu-ral killer (NK) cells numbers and suppressed T helper type 1-mediated immune responses [150, 151].”
Ding, J., Sun, Y., Sulaiman, Z., Li, C., Cheng, Z., & Liu, S. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s395553 · Cited by 17
“CD276 suppressed the proliferation of CD4 and CD8 T cells and inhibited the activity of NK cells.(9,10) Recently, Wang et al reported that CD276 was hijacked by cancer stem cells (CSCs) to evade immune surveillance in head and neck squamous carcinoma (HNSC).”
BackgroundResultWang, F., Wang, Y. Y., Li, J., You, X., Qiu, X. H., Wang, Y. N., & GAO, F. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105636 · Cited by 12
Preparation and application of a novel monoclonal antibody specific for human B7-H3
Shi, J., Zhang, D., CUI, Z.-C., & Wang, H. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5288 · Cited by 11
“2IgB7-H3 and 4IgB7-H3 have similar functions and can down-regulate T cell responses (10,11).”
Perspectives of Immune Suppression in the Tumor Microenvironment Promoting Oral Malignancy
Kondoh, N., Mizuno‐Kamiya, M., Takayama, E., Kawati, H., Umemura, N., Yamazaki, Y., Mitsudo, K., & Tohnai, I. (2018) · The Open Dentistry Journal · doi:10.2174/1874210601812010455 · Cited by 11
“[42] Suh WK, Gajewska BU, Okada H, et al.”
BackgroundInhibitory axes impacting on the activity and fate of Innate Lymphoid Cells
Bottino, C., Dondero, A., & Castriconi, R. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.100985 · Cited by 11
Reduced Serum B7-H3 Levels in Patients with Ankylosing Spondylitis
Yan, R., Hu, Y., Yu, P., Wen, H., Feng, P., & Yang, S. F. (2015) · Inflammation · doi:10.1007/s10753-014-0103-z · Cited by 11
“However, subsequent results indicated that B7-H3 downregulated Th1-mediated immune responses[10, 11].”
Anterior Pituitary Progenitor Cells Express Costimulatory Molecule 4Ig-B7-H3
Nagai, Y., Aso, H., Ogasawara, H., Tanaka, S., Taketa, Y., Watanabe, K., Ohwada, S., Rose, M. T., Kitazawa, H., & Yamaguchi, T. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6073 · Cited by 11
“In both the human and mouse, B7-H3 binds to an unidentified receptor expressed on activated T cells and NK cells, and exerts an inhibitory function on their cell-mediated responses (17, 25, 28).”
BackgroundB7-H3/CD276: Novel Immune Checkpoint and Jack of All Trades
Larkin, B., Nishizaki, D., Miyashita, H., Lee, S., Nikanjam, M., Eskander, R. N., Jensen, T. J., Pabla, S., Conroy, J. M., DePietro, P., et al. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s534666 · Cited by 11
MYC at the tumor–immune interface: mechanisms of immune escape and immunotherapy resistance
González-Larreategui, Í., Martin, M. C., Casacuberta‐Serra, S., & Soucek, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1738440 · Cited by 12
“In the case of B7-H3 immune checkpoint, its MYC-driven overexpression inhibits T and NK cell-mediated immune surveillance (142, 143).”
Upregulation of the B7/CD28 family member B7-H3 in bladder cancer
Wu, D., Zhang, Z., PAN, H., FAN, Y., Qü, P., & Zhou, J. (2014) · Oncology Letters · doi:10.3892/ol.2014.2828 · Cited by 11
Hashimoto, H., Kasteleiner, P., Kressin, J., Müller, F., Bühring, H., Handgretinger, R., & Schilbach, K. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01307-9 · Cited by 10
“report that CD276 is a negative regulator that preferentially affects TH1 responses, as it downregulates TH1-mediated immune responses and inhibits the secretion of the cytokine IFN-γ [44].”
BackgroundXu, Y., Yu, L., Hao, C., Wang, Y., Zhu, C., Ji, W., Li, Y., Li, G., Chen, Z., & Yan, Y. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.05.014 · Cited by 12
Sun, Y., Zhou, X., Lucas, E., Chen, L., Zhang, H., Chen, H., & Zhou, F. (2023) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.345 · Cited by 10
“B7-H3 is a member of the B7 family of cell surface molecules, which can inhibit the activation and function of T-cells [37], and serves as a negative regulator in T-cell-mediated immune responses to convey protection of tumor cells from immune attack [38].”
BackgroundKim, N. I., Park, M. H., Cho, N., & Lee, J. S. (2021) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001001 · Cited by 9
Huang, M., Luo, J., Ji, X., Hu, M., Xue, Y., & Liu, Q. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106512 · Cited by 11
Genome-wide identification and evolutionary analysis of B7-H3
Duan, H., & Huang, M. (2012) · International Journal of Data Mining and Bioinformatics · doi:10.1504/ijdmb.2012.049247 · Cited by 9
Lymphocyte Subpopulations of the Skin
Cavani, A., Nuzzo, S. D., Girolomoni, G., & Panfilis, G. D. (2004) · CRC Press eBooks · doi:10.1201/b14248-9 · Cited by 9
Xu, J., Gao, F., Liu, Y.-A., Zhang, X., Chen, H., Zhu, X., Song, H., Qian, F., Li, M., Yang, C. G., et al. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-018-0534-1 · Cited by 9
Jang, B., Park, Y.-K., Choi, I., Kim, S.-P., Hwang, J., Baek, W., Suh, M., Mun, K.-C., & Suh, S.-I. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.6.1439 · Cited by 9
Commentary: Regulated equilibrium between opposite signals: a general paradigm for T cell function?
Moretta, A., & Bottino, C. (2004) · European Journal of Immunology · doi:10.1002/eji.200425388 · Cited by 9
Ke, T., Chen, C.-Y., Chen, W. T., Tsai, Y., Chiang, S., Huang, C.-H., Lin, Y. E., Chen, T.-H., Chen, T.-W., Liang, J., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01132-x · Cited by 10
Unlocking new frontiers: novel immune targets for next-generation cancer immunotherapy
Zaheer, S., & Sureka, N. (2025) · Korean Journal of Clinical Oncology · doi:10.14216/kjco.24322 · Cited by 9
“Suh et al. discovered that murine B7-H3 inhibits T cell proliferation [80].”
Părângă, T. G., Tanasa, M. P., Constantinescu, D., Iftimi, E., Plesca, C. E., Miftode, I.-L., Cianga, P., & Miftode, E. G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1464480 · Cited by 10
Future of Immune Checkpoint Inhibitors
Maawy, A. A., & Ito, F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00012-3 · Cited by 10
Chen, C., Zhu, Y., Qu, Q., Ge, Y., Huang, J., Wang, Y., & Zhang, X. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31818c8816 · Cited by 8
Zhou, Y., Zhang, G., Zhang, W., Wei, X., Hou, J., & Huang, Y. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820971649 · Cited by 11
“Subsequent experiments have also confirmed that B7-H3 is an immunosuppressor that inhibits the immune response in vivo by down regulating the type I helper T cell-mediated immune response.(3) Recently, our group confirmed that B7-H3 played an important role in the mononuclear macrophagocytemediated inflammatory respon…”
BackgroundGuo, G., Cao, D., Xu, H., Ruan, Z., Fei, L., Xie, Z., Wu, Y., & Chen, Y. (2012) · Pathology International · doi:10.1111/j.1440-1827.2012.02856.x · Cited by 11
Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma
Li, D., Andaloori, L., Crowe, M., Lin, S., Hong, J., Zaidi, N., & Ho, M. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.10.021 · Cited by 7
Kim, N. I., Park, M. H., & Lee, J. S. (2019) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000817 · Cited by 7
Cloning and Characterization of Porcine 4Ig-B7-H3: A Potent Inhibitor of Porcine T-Cell Activation
Chen, W., Hou, Z., Li, C., Xiong, S., & Liu, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021341 · Cited by 7
“Considering that monocytes are important precursors of DCs, we analyzed the B7-H3 expression on porcine monocytes.”
BackgroundInfluentialHwang, J. Y., Jeong, J.-M., Kwon, M., Seo, J. S., Hwang, S. D., Son, M.-H., Bae, J.-S., Choi, K.-M., Cho, D., Jeswin, J., et al. (2017) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2017.12.021 · Cited by 7
Transplant tolerance through costimulation blockade - are we there yet?
Vadivel, N. (2007) · Frontiers in bioscience · doi:10.2741/2283 · Cited by 7
The Many Sounds of T Lymphocyte Silence
Melero, I., Arina, A., & Chen, L. (2005) · Immunologic Research · doi:10.1385/ir:33:2:135 · Cited by 7
“The observation from B7-H3‐deficient mice, however, are controversial with one report that showed an improved Th1 responses ( 98 ) whereas another demonstrated an inhibited acute and chronic allograft rejection (99).”
BackgroundFrom tumor immunity to precision medicine: the next step in B7-H3/CD276 research
Fang, H., Liu, Y., Wang, G., & Liu, H.-J. (2025) · Medical Review · doi:10.1515/mr-2025-0003 · Cited by 6
Osei-Hwedieh, D. O., He, L., Wang, K., Fan, S., Ferrone, S., Wang, X., & Schwab, J. H. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102538 · Cited by 7
“B7-H3 is a potent regulator of T cell activation and proliferation, making it an attractive target for CAR T cell therapy [4,8].”
Ozaki, H., Inoue, N., Iwatani, Y., Watanabe, A., Yamamoto, M., Kitahara, N., Tanikawa, S., Noguchi, Y., Hidaka, Y., & Watanabe, M. (2023) · Clinical Endocrinology · doi:10.1111/cen.14923 · Cited by 6
“B7‐H3 is weakly expressed in activated T cells, B cells, monocytes, dendritic cells (DCs), and some tumour cell lines.(9,10) B7‐H3 expression is upregulated in stimulated monocytes and monocyte‐derived DCs.”
BackgroundInfluentialLi, J., Zhou, B., Wang, S., Ouyang, J., Jiang, X., Wang, C., Zhou, T., Zheng, K., Wang, J., & Wang, J. (2024) · Bioengineering · doi:10.3390/bioengineering11040381 · Cited by 6
“In nonmalignant tissues, B7-H3 primarily assumes an inhibitory role in adaptive immunity by suppressing T-cell activation and proliferation [13,14].”
BackgroundTian, X., Li, Y., Liu, G., & Li, X. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18360 · Cited by 7
Asakawa, A., Yoshimoto, R., Kobayashi, M., Izumi, N., Maejima, T., Deguchi, T., Kubota, K., Takahashi, H., Yamada, M., Ishibashi, S., et al. (2024) · Cancers · doi:10.3390/cancers16112140 · Cited by 6
“B7-H3 inhibits T-cell proliferation [23,24] and is associated with the inhibition of CD8 + T-cell upregulation, whereas aberrant B7-H3 expression is implicated in the elimination and dysfunction of CD8 + T-cell infiltration in head and neck cancer [25].”
BackgroundShakiba, S., Haddadi, N., Afshari, K., Lubov, J. E., Raef, H. S., Li, R., Yıldız-Altay, Ü., Daga, M., Refat, M. A., Kim, E., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-60937-5 · Cited by 9
“B7-H3 plays a pivotal role in mediating the suppressive effects of DCs on T cells and downregulating Th1 responses 32 .”
Chen, Y., Yang, H., Xu, S., Shen, J., Xu, W., Shao, M., & Pan, F. (2021) · International Journal of Immunogenetics · doi:10.1111/iji.12559 · Cited by 6
Tang, H., Zhang, Y., Zhao, S., & Song, C. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100580 · Cited by 8
Immunotherapy and Cancer Therapeutics: Why Partner?
Emens, L. A., & Jaffee, E. M. (2007) · Elsevier eBooks · doi:10.1016/b978-012372551-6/50076-6 · Cited by 9
Moorthy, T., Yalamandala, B. N., Huynh, T. M. H., Lien, H., Pan, W.-C., Iao, H. M., Chang, Y., & Hu, S. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01935-4 · Cited by 5
“Upregulation of B7-H3 (B7 family immune checkpoint molecule) in the lung has been reported to facilitate pro-cancer and immunosuppressive functions, and CD47 blockade improves phagocytosis in lung cancer models [120, 125–127].”
Glazer, S. E., Sutton, M. N., Yang, P., Pisaneschi, F., Sebastian, M. M., Gammon, S. T., & Piwnica-Worms, D. (2026) · Theranostics · doi:10.7150/thno.123285 · Cited by 5
Doll, S., Schweizer, L., Bollwein, C., Steiger, K., Pfarr, N., Walker, M., Wörtler, K., Knebel, C., von Eisenhart‐Rothe, R., Hartmann, W., et al. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100511 · Cited by 7
Zhou, Q., Xu, J., Chen, X., Ouyang, J., Mao, C., & Zhang, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1445526 · Cited by 5
HIV status alters immune cell infiltration and activation profile in women with breast cancer
Bauer, M., Santos, P. S. C., Wilfer, A., van den Berg, E. J., Zietsman, A., Vetter, M., Kaufhold, S., Wickenhauser, C., dos‐Santos‐Silva, I., Chen, W. C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59408-8 · Cited by 5
“Furthermore, the expression of several ICP molecules like PD-1 47 , LAG3 48,49 , CTLA4 50 and CD276 51,52 is increased by IFN-γ signaling.”
The challenges and progress of CAR-T cell therapy in the treatment of solid tumors
Cui, K., He, W., Huang, N., Zhu, S., Jiang, D., Yang, W., Zeng, Y., Farooq, M. A., & Xu, G. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05329-5 · Cited by 6
Nagy, N. A., Celant, S. G., van Capel, T. M. M., Sparrius, R., Vigario, F. L., van Ree, R., Slütter, B., Geijtenbeek, T. B. H., Tas, S. W., & de Jong, E. C. (2025) · Journal of Immunology Research · doi:10.1155/jimr/2208155 · Cited by 6
“Lack of induction of IL-10 producing T cells and inhibition of Th1 cells could be due to reduced expression of ICOS-L and B7H3 in VD3-treated skin DCs. ICOS-L and B7H3 are key coinhibitory molecules involved in induction of IL-10 producing T cells and inhibition of Th1 cells, respectively [72, 73].”
Chen, T., Li, X., Hong, D., Yin, L., Fang, C., Chen, X., Yang, Z.-X., Zhao, P., Hu, L., Wang, Z., et al. (2025) · Thyroid · doi:10.1177/10507256251372644 · Cited by 5
“20 – 22 The absence of a known receptor for B7-H3 makes this molecule dif fi cult to target pharmacologically.”
Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer
Bote, H., Mesas, A., Baena, J., Herrera, M., & Paz-Ares, L. G. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2113377 · Cited by 6
Weidle, U. H., & Birzele, F. (2023) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20413 · Cited by 7
“The ligand for B7H3 remains to be identified and B7H3 can inhibit proliferation of CD4+ and CD8+ T-cells (43).”
BackgroundHagelstein, I., Mattern, S., Wang, K., Haueisen, Y. E., Greiner, S. M., Englisch, A., Staebler, A., Singer, S., & Lutz, M. S. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s521008 · Cited by 5
“35,36 Mechanistically, B7-H3 has been shown to suppress T cell proliferation and cytokine production, 37,38 as well as to inhibit NK cell-mediated cytotoxicity.”
T cell costimulatory pathways in allograft rejection and tolerance: what's new?
Habicht, A., & Sayegh, M. H. (2007) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e328012b651 · Cited by 5
Baulenas‐Farres, M., Paco, S., Marino, F., Mohr, J., Panisello, C., Balaguer‐Lluna, L., Aschero, R., Cuadrado‐Vilanova, M., Resa‐Pares, C., Rodríguez, E., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf132 · Cited by 5
“15 B7-H3 inhibits the proliferation of CD8 + and CD4 + T cells 29 and promotes the recruitment and M2-like polarization of the microglia.”
An EBNA1-YAP signaling axis drives immune escape through CD276 in EBV-associated gastric cancer
Huang, B., Liu, M., Duan, Y., Guo, J., Wang, Z., Dou, Y., Wang, M., Abuhaidar, O., Sun, H., Kee, L. S., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08251-2 · Cited by 4
“CD276 (B7-H3) is a relatively novel immune checkpoint molecule within the B7 family, recognized as an orphan ligand that plays dual roles in immune modulation, exhibiting both co-stimulatory and co-inhibitory effects [18 – 20].”
B7-H3 Promoted Sperm Motility in Humans
Wei, X., Li, Z., Zhang, G., Yuan, H., Lv, J., Jiang, Y., Zhang, W., Huang, Y., & Hou, J. (2013) · Urology · doi:10.1016/j.urology.2013.07.078 · Cited by 4
Koldej, R. M., Prabahran, A. A., Tan, C. W., Ludford‐Menting, M., Morgan, H., Holzwart, N., Davis, M. J., & Ritchie, D. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213560 · Cited by 4
“Expressed by a wide range of cells, including activated T cells, NK cells, dendritic cells, and macrophages (35 – 37), along with non-hematopoietic cells, including fi broblasts, synoviocytes, osteoblasts, and epithelial cells (38 – 40), with both immunostimulatory (41, 42) and inhibitory (43, 44)…”
BackgroundGeneration of B7 ‐ H3 isoform regulated by ANXA2 / NSUN2 / YBX1 axis in human glioma
Shen, Y., Ma, C., Li, X., Li, X., Wu, Y., Yang, T., Hu, Y., Liu, C., Shen, H., Pin, G., et al. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18575 · Cited by 4
“8,9 Therefore, the regulatory role of B7-H3 on immune cells has been a subject of ongoing debate.”
BackgroundB7 homolog 3 in pancreatic cancer
Perović, D., Pjević, M. D., Perović, V., Grk, M., Rasic, M., Miličković, M., Mijović, T., & Rašić, P. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i31.3654 · Cited by 5
Identification of the B7-H3 Interaction Partners Using a Proximity Labeling Strategy
Liao, S., Huang, J. M., Lupala, C. S., Li, X., Li, N., & Li, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041731 · Cited by 5
“It shares sequence and structural identity with other B7 family members [2,3].”
A Novel Monoclonal Antibody Against Mouse B7-H3 Developed in Rats
Yan, R., Yang, S. F., Sun, J., Chen, X., Zhang, G., Feng, P., & Zhang, X. (2012) · Hybridoma · doi:10.1089/hyb.2012.0008 · Cited by 4
“But subsequent results indicated that B7-H3 down-regulated Th1-mediated immune responses.((7,8)) Luo and colleagues demonstrated that B7-H3 had antitumor activity in mice.”
ResultImmune Co-signaling to Treat Cancer
Callahan, M. K., Wolchok, J. D., Allison, J. P., & Sharma, P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4732-0_8 · Cited by 4
T-Cell Costimulation and Coinhibition in Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect
Wu, Y., Anasetti, C., & Yu, X. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812630-1.00011-6 · Cited by 6
Chung, J., Choi, M., Kim, M. G., Park, S. K., & Kim, Y. M. (2022) · American Journal of Rhinology and Allergy · doi:10.1177/19458924211072364 · Cited by 4
Dendritic Cells and Their Role in Linking Innate and Adaptive Immune Responses
Lipscomb, M. F., Wilder, J. A., & Masten, B. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-33785-2_2 · Cited by 4
Steinberger, P. (2015) · Blood · doi:10.1182/blood-2015-04-638304 · Cited by 4
Li, M., Cao, J., Wang, Y., Zhao, Z., Ai, L., & Zhang, K. (2025) · Medicine · doi:10.1097/md.0000000000042566 · Cited by 4
Zhao, W., Luo, Q., Yuan, B., Duan, H., & Jiang, S. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.153 · Cited by 13
Prognostic Role of B7-H3 (CD276) Expression in Initial Biopsies of Metastatic Prostate Cancer
Yusuf, A., & Pramanik, P. (2025) · Onco · doi:10.3390/onco5030038 · Cited by 16
Discovery of tumor antigens in renal cell carcinoma and prospects for clinical application
Марсельевна, К. Э., Enikeeva, K., Mukhamadeev, R. R., Динаровна, А. Д., Вакилевна, Ш. Ю., Shmelkova, P., Gainullina, D. K., Trifonova, D., Gattinger, P., Docena, G. H., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1771006 · Cited by 4
“The ability of B7-H3 to inhibit the proliferation of CD4 + and CD8 + T cells has been discovered (110).”
Tumor vascular normalization by B7-H3 blockade augments T lymphocyte-mediated antitumor immunity
Dai, X., Cao, B., Liu, X., Meng, W., Qiu, Y., Sun, Y., Zhang, L., Li, D., Liu, Z., Li, D., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177334 · Cited by 5
Haberecker, M., Rüschoff, J. H., Andriakopoulou, C., Gray, S. G., Nackaerts, K., de Perrot, M. E., Brčić, L., Nadal, E., Tsimpoukis, S., Ampollini, L., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00675 · Cited by 3
Co-expression of B7-H3 and LAG3 represents cytotoxicity of CD4+ T cells in humans
Tamura, Y., Ohki, S., Nagai, H., Yoshizato, R., Nishi, S., Jin, Y., Kitajima, Y., Guo, Y., Ichinohe, T., Okada, S., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1560383 · Cited by 3
Zhou, J., Blevins, L. K., Crawford, R. B., & Kaminski, N. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884203 · Cited by 4
“One example is B7-H3 which has recently been described in promoting immune suppression in the tumor microenvironment (79, 80).”
Background(2005) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.15.6.745 · Cited by 3
“Although two studies in mice [10,14] have corroborated the findings obtained here with human T cells in vitro, other studies have lent support to the opposite conclusion that B7-H3 acts to augment T cell activation.”
BackgroundResultInfluentialFramework of Intrinsic Immune Landscape of Dormant Prostate Cancer
Wong, N. K. Y., Dong, X., Lin, Y., Xue, H., Wu, R., Lin, D., Collins, C. C., & Wang, Y. Z. (2022) · Cells · doi:10.3390/cells11091550 · Cited by 5
“B7-H3 can exert its inhibitory influence on Th1 response [64], T cell effector function [65], and NK cytolytic activity [66], potentially promoting immune evasion.”
BackgroundThe evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma
Tang, G., Liu, J., Qi, L., & Li, Y. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15504 · Cited by 3
“In different studies, the influence of B7-H3 on patient prognosis was reversed.(147,148) Therefore, the role of B7-H3 in tumour immunity is probably related to different tumour microenvironments.”
BackgroundDing, S., Shan, Y., Sun, L., Li, S., Jiang, R., Chang, X., Huang, Z., Sun, J., Liu, C., Fang, C., et al. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00592-7 · Cited by 3
Soluble forms of immune checkpoints in ovarian cancer
Kovaleva, O. V., Belova, T. P., Kushlinsky, D. N., Korotkova, E. A., Алексеевна, П. П., Gratchev, A. N., Zinoviev, S. V., Терешкина, И. В., Sokolov, N. Y., Kudlay, D. A., et al. (2021) · Russian Clinical Laboratory Diagnostics · doi:10.51620/0869-2084-2021-66-2-80-86 · Cited by 3
Guo, X., Yu, S., Ren, X., & Li, L. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e19222 · Cited by 4
Zhang, Z., Xu, J., Song, Z., Zhang, J., Lin, Y., & Ouyang, J. (2024) · Cancer Control · doi:10.1177/10732748241250181 · Cited by 3
“27,28 The earliest discovery was that programmed cell death-1 (PD-L1; also known as B7-H1) is expressed on antigen-presenting cells.”
BackgroundDifferent expression of B7-H3 in the caput, corpus, and cauda of the epididymis in mouse
Li, K., Wei, X., Zhang, G., Li, M., Zhang, X., Zhou, C., Hou, J., & Yuan, H. (2017) · BMC Urology · doi:10.1186/s12894-017-0215-5 · Cited by 3
“had a negative regulatory function in T cell -mediated immune responses both in vitro and in vivo [12, 13].”
BackgroundGOLM1 as a Potential Therapeutic Target Modulates B7-H3 Secretion to Drive Ovarian Cancer Metastasis
Guan, J., Qin, Y.-P., Deng, G., & Zhao, H. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/5151065 · Cited by 6
The Mouse TrapHow Well Do Mice Model Human Immunology?
HUGHES, C., & Mestas, J. (2007) · Elsevier eBooks · doi:10.1016/b978-012369454-6/50093-5 · Cited by 3
SH3GL1 mediates B7-H3 recycling and enhances the immune escape in non-small cell lung cancer
Lan, S., & Liu, C. (2025) · The International Journal of Biological Markers · doi:10.1177/03936155251367774 · Cited by 2
Prognostic and therapeutic roles of B7-H3 and B7-H4 in prostate cancer
Hu, Y., Yang, W., Guo, S., & Huang, D. (2026) · Discover Oncology · doi:10.1007/s12672-026-04926-0 · Cited by 2
“Combination therapeutic strategies, such as radiotherapy and androgen-receptor pathway inhibitors (ARPI), are shown as potential complementary approaches to B7-H3-targeted treatments production (e.g., IFN-γ, IL-2), and cytolytic activity [11, 12, 28].”
Bley, I. A., Behrens, S., Spohn, M., Müller, I., & Schattling, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020527 · Cited by 2
Shojo, K., Tanaka, N., Murakami, T., Anno, T., Teranishi, Y., Takamatsu, K., Mikami, S., Imamura, T., Matsumoto, K., & Oya, M. (2024) · Laboratory Investigation · doi:10.1016/j.labinv.2024.102131 · Cited by 2
Assessment of plasma B7-H3 levels in pediatric patients with different degrees of surgical stress
Li, Y., Yuan, Q., Huang, J., Li, Y. P., Pan, J., Feng, X., Zhang, X. G., Wang, J. H., & Wang, J. (2016) · BMC Pediatrics · doi:10.1186/s12887-016-0655-1 · Cited by 2
“It has been well-documented that B7H3, as a co-stimulatory molecule, participates in both adaptive and innate immune responses [3, 4].”
High constitutive B7-H3 expression on human keratinocytes supports T cell immunity
Quandt, D., Fiedler, E., Müller, A., Marsch, W. C., & Seliger, B. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.02.287 · Cited by 2
Adams, S., Bhardwaj, N., & O’Neill, D. W. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6087-8_11 · Cited by 2
Sakthivel, P., Wang, X., Gharizadeh, B., Giscombe, R., Pirskanen, R., Nyrén, P., & Lefvert, A. K. (2006) · Journal of Genetics · doi:10.1007/bf02935335 · Cited by 2
Bottomley, M. J., McKenna, M., Li, Z., Zibandeh, N., Kumaran, G. K., Hamid, M. A., Antoun, E., Ieremia, E., Brewer, L., Van, T. M., et al. (2025) · medRxiv · doi:10.1101/2025.05.23.25327735 · Cited by 2
Metadata
- Authors
- Suh, W.-K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., Dawicki, W., Duncan, G. S., Bukczynski, J., Plyte, S., Elia, A., Wakeham, A., Itie, A., Chung, S., Da Costa, J., Arya, S., Horan, T., Campbell, P., Gaida, K., Ohashi, P. S., Watts, T. H., Yoshinaga, S. K., Bray, M. R., Jordana, M., & Mak, T. W.
- Affiliations
- University of Toronto (CA)
- McMaster University (CA)
- Amgen (United States) (US)
- Corresponding author
- Suh, Woong-Kyung
- Mak, Tak W
- ORCID
- Venue
- Nature Immunology
- Published
- 2003-08-17
- Volume
- 4
- Issue
- 9
- Pages
- 899-906
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2052644931
- Cited by
- 576
- References
- 47
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 32 · 2023: 30 · 2022: 37 · 2021: 48 · 2020: 35 · 2019: 29 · 2018: 12 · 2017: 21 · 2016: 20 · 2015: 25 · 2014: 9 · 2013: 18 · 2012: 29
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- B7-H3, B7 family, T cell proliferation, airway inflammation, interferon-gamma, IL-4, dendritic cells, experimental autoimmune encephalomyelitis, negative regulation of immune response, gene targeting
- MeSH terms
- Animals, Autoantibodies, Dendritic Cells, Encephalomyelitis, Autoimmune, Experimental, Flow Cytometry, Interferon-gamma, Lymphocyte Activation, Lymphocytic choriomeningitis virus, Mice, Inbred C57BL, Orthomyxoviridae, Receptors, Antigen, T-Cell, Vesicular stomatitis Indiana virus, Down-Regulation, Interleukin-4, B7-1 Antigen, Mice, Knockout, Th1 Cells, Mice, B7 Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.